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Cystic fibrosis (CF) is caused by mutations that disrupt the
plasmamembrane expression, stability, and function of the cys-
tic fibrosis transmembrane conductance regulator (CFTR) Cl
channel. Two small molecules, the CFTR corrector lumacaftor
and the potentiator ivacaftor, are nowused clinically to treatCF,
although some studies suggest that they have counteracting
effects on CFTR stability. Here, we investigated the impact of
these compounds on the instability of F508del-CFTR, the most
common CFmutation. To study individual CFTRCl channels,
we performed single-channel recording, whereas to assess
entire CFTR populations, we used purified CFTR proteins and
macroscopicCFTRCl currents.At 37 °C, low temperature-res-
cued F508del-CFTR more rapidly lost function in cell-free
membrane patches and showed altered channel gating and cur-
rent flow through open channels. Compared with purified wild-
type CFTR, the full-length F508del-CFTR was about 10 °C less
thermostable. Lumacaftor partially stabilized purified full-
length F508del-CFTR and slightly delayed deactivation of indi-
vidual F508del-CFTR Cl channels. By contrast, ivacaftor fur-
ther destabilized full-length F508del-CFTR and accelerated
channel deactivation. Chronic (prolonged) co-incubation of
F508del-CFTR-expressing cells with lumacaftor and ivacaftor
deactivated macroscopic F508del-CFTR Cl currents. How-
ever, at the single-channel level, chronic co-incubation greatly
increased F508del-CFTRchannel activity and temporal stability
in most, but not all, cell-free membrane patches. We conclude
that chronic lumacaftor and ivacaftor co-treatment restores sta-
bility in a small subpopulation of F508del-CFTR Cl channels
but that the majority remain destabilized. A fuller understand-
ing of these effects and the characterization of the small
F508del-CFTR subpopulation might be crucial for CF therapy
development.
Cystic fibrosis (CF)8 is a common life-shortening inherited
disease, mostly affecting people of European origin (1). The
disease affects multiple organ systems throughout the body,
especially the respiratory airways and intestine, leading to the
blockage of ducts and tubes by thick tenacious mucus and a
failure of host defense systems (1, 2). CF is caused bymutations
in the cystic fibrosis transmembrane conductance regulator
(CFTR) (3), a unique ATP-binding cassette (ABC) transporter
that functions as a Cl channel with complex regulation (4).
Located in the apical membrane of epithelia, CFTR plays a piv-
otal role in transepithelial ion transport, regulating the quantity
and composition of epithelial secretions (5).
To date,2,000 mutations have been identified in the CFTR
gene (see the Hospital for Sick Children in Toronto Cystic
Fibrosis Mutation Database), although the vast majority are
very rare and not all lead to CF (1). By far the most common
disease-causing mutation, with a prevalence as high as 90%, is
F508del, the deletion of the phenylalanine residue at position
508 of the CFTR amino acid sequence (1). F508del affects a
residue located in a crucial position on the surface of the first
nucleotide-binding domain (NBD1) (6). Structural studies
reveal that the absence of Phe-508 causes local structural
changes to the ABC -subdomain of NBD1, mainly affecting
the loop spanning residues 509–511 (7). However, loss of Phe-
508 disrupts domain-domain interactions critical for correct
assembly and function of CFTR (8–11). F508del-CFTR is rec-
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ognized as abnormal by the endoplasmic reticulum quality
control machinery and is ubiquitinated and degraded by the
proteasome (12, 13). Thus, F508del principally disrupts the pro-
cessing and intracellular transport of CFTR protein. Neverthe-
less, any F508del-CFTR that escapes to the plasma membrane
exhibits two further abnormalities: reduced stability (14) and
altered channel gating (15).
To overcome the defective expression and function of CF
mutants, two classes of small molecules have been developed
termed CFTR correctors and CFTR potentiators (12). CFTR
correctors (e.g. lumacaftor; VX-809) (16) traffic mutant protein
to the plasma membrane. By contrast, CFTR potentiators (e.g.
ivacaftor; VX-770) (17) strongly augment channel gating.
Although neither lumacaftor nor ivacaftor, by themselves, have
clinical benefit for CF patients with the F508del mutation (18,
19), combination therapywith the two drugs has improved lung
function and disease stability (20), leading to the approval in
2015 of lumacaftor-ivacaftor combination therapy.
When compared with the clinical benefit achieved by iva-
caftor in CF patients with the gatingmutation G551D (21), that
observed with lumacaftor-ivacaftor combination therapy in
CF patients homozygous for F508del appears less marked
(20). One potential explanation of these data is that
lumacaftor only partially rescues the plasma membrane
expression of F508del-CFTR; combinations of correctors
will probably be required for complete rescue (22, 23). How-
ever, chronic treatment of F508del-CFTR-expressing cells with
ivacaftor destabilizes lumacaftor-rescued F508del-CFTR Cl
currents (24, 25). Although this result argues that ivacaftor
might have counterproductive effects on F508del-CFTR, other
studies offer alternative explanations, including limited efficacy
of lumacaftor (26) and the action of lumacaftor-ivacaftor com-
bination therapy on mucociliary clearance (27).
Thus, the aims of this study were 2-fold: first, to understand
better the impact of F508del on CFTR stability, and second, to
investigate the effects of lumacaftor and ivacaftor on the insta-
bility of F508del-CFTR. To address our aims, we used biochem-
ical and functional assays, purified CFTR protein, and recom-
binant CFTR expressed in cultured cells. We discovered that
the F508del mutation destabilized purified full-length CFTR
protein by 10 °C and deactivated CFTR Cl channels in
excised membrane patches by the time-dependent loss of both
channel gating and current flow through open channels. We
found that lumacaftor and ivacaftor had complex effects on
F508del-CFTR. Whereas lumacaftor thermally stabilized puri-
fied full-length F508del-CFTR protein, ivacaftor destabilized it.
At the macroscopic level, chronic ivacaftor treatment acceler-
ated the temporal deactivation of lumacaftor-rescued F508del-
CFTR Cl currents. However, at the single-channel level,
chronic lumacaftor and ivacaftor co-treatment greatly
increased F508del-CFTR channel activity and stability in
most, but not all, excisedmembrane patches.We conclude that
lumacaftor-ivacaftor combination therapy rescues a small sub-
population of F508del-CFTR Cl channels. We speculate that
understanding the heterogeneity of CFTR populations in epi-
thelial cells might be crucial for CF therapy development.
Results
F508del, butNotG551D,Destabilizes CFTRChannel Activity
in Cell-free Membrane Patches at 37 °C—Here, we investigated
the instability of the most common CF mutant F508del-CFTR
and its rescue by the CFTR corrector lumacaftor (16) and the
CFTR potentiator ivacaftor (17). We analyzed the functional
instability of F508del-CFTR in excised membrane patches and
polarized epithelia at 37 °C to relate molecular defects to tissue
dysfunction. To complement these studies, we examined the
thermal instability of full-length F508del-CFTR protein in
membranes and after purification.As controls, we studiedwild-
type CFTR and the CF mutation G551D, which severely dis-
rupts CFTR channel gating without altering protein processing
and stability (28–30).
Fig. 1A shows representative single-channel recordings of
wild-type CFTR, F508del-CFTR, and G551D-CFTR in excised
inside-out membrane patches at 37 °C after channel activation
was complete. The gating pattern of wild-type CFTR was char-
acterized by bursts of channel openings interrupted by brief
flickery closures, separated by longer closures between bursts
(Fig. 1A). Consistent with previous data (e.g. see Refs. 29 and
31–33), F508del and G551D severely decreased the frequency
of channel openings with the result that open probability (Po)
(or apparent Po (Po(app)) (30)) was reduced dramatically (Fig. 1,
A andD). By contrast, neither F508del nor G551D affected cur-
rent flow through fully open CFTR Cl channels (Fig. 1, A–C).
However, close inspection of single-channel recordings
revealed that F508del-CFTR also opened partially to a smaller
current level, a subconductance state (Fig. 1A). These partial
channel openings are more clearly seen in the single-channel
current amplitude histogram of F508del-CFTR as a shoulder to
the closed channel amplitude, 29% of the value of the fully open
state (Fig. 1, B (middle) and C). Openings to subconductance
states were observed in 37 of 39 recordings of F508del-CFTR in
excised membrane patches and were always associated with
channel deactivation (see below). By contrast, openings to sub-
conductance states were only observed in 4 of 18 recordings of
wild-type CFTR and were not associated with channel deacti-
vation. We did not quantify the Po of the subconductance state
of F508del-CFTR because of its small current amplitude and
variable gating pattern (76).
The F508del mutation destabilizes full-length CFTR protein
at the plasma membrane (14), leading to accelerated rundown
of CFTR Cl channels at 37 °C (e.g. see Ref. 34). To investigate
the impact of CF mutations on CFTR stability, we used Po val-
ues tomonitor the duration of channel activity in excisedmem-
brane patches at 37 °C (32). Fig. 2 illustrates the single-channel
activity of wild-type CFTR, F508del-CFTR, and G551D-CFTR
in excised membrane patches over the first 9 min of recordings
at 37 °C after channel activation was complete (for details, see
the legend to Fig. 2). Wild-type CFTR and G551D-CFTR both
demonstrated stable and sustained channel activity, albeit that
of G551D-CFTR was greatly reduced compared with wild-type
CFTR (Fig. 2, A–D).
When rescued by low temperature incubation, F508del-
CFTR exhibited sustained low level channel activity at 23 °C
(32). By contrast, at 37 °C its activity was unstable and declined
Instability of F508del-CFTR
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rapidly over time (Fig. 2,E and F). Comparison of normalizedPo
values reveals that rundown of F508del-CFTR was 50% com-
plete around 3 min and complete within 7 min (Fig. 2E). Visual
inspection of single-channel records (Figs. 2F and 3) suggests
that F508del-CFTR rundown involves both changes in channel
gating and current flow through open channels. Reflecting the
decline in F508del-CFTR Po, the change in gating pattern was
characterized by reduced frequency of channel openings before
complete channel deactivation (Figs. 2 (E and F) and 3). The
change in current flow through F508del-CFTR accompanying
channel rundown was characterized by increased frequency of
partial channel openings to a subconductance state (e.g. Fig. 3).
Thus, F508del causes CFTR instability by perturbing both
channel gating and current flow through the CFTR pore.
Effects of Ivacaftor and Lumacaftor on the Instability of
F508del-CFTR Cl Channels—Some studies suggest that iva-
caftor destabilizes F508del-CFTR Cl channels (24, 25). To
investigate the action of ivacaftor on F508del-CFTR,we studied
single channels in excisedmembrane patches at 37 °C, compar-
ing acute and chronic effects of the small molecule on F508del-
CFTR Cl channels rescued by lumacaftor.
Fig. 2, E–H, compares the single-channel activity and stabil-
ity of F508del-CFTR rescued by lumacaftor (3 M for 24 h at
37 °C) with low temperature correction (48–72 h at 27 °C).
Consistent with previous results (35), lumacaftor-rescued
F508del-CFTR exhibited a gating defect, and its initial Po at
37 °C following complete channel activation was not different
from that of low temperature-rescued F508del-CFTR (p 0.74;
unpaired t test) (Fig. 2, E andG). Like low temperature-rescued
F508del-CFTR, lumacaftor-rescued F508del-CFTR was unsta-
ble and deactivated over time (Fig. 2, E–H). Comparison
of normalized Po values suggests that lumacaftor-rescued
F508del-CFTR Cl channels were slower to deactivate, but the
difference was not statistically significant (low temperature-
rescued F508del-CFTR, 50% normalized Po  3.5 min;
lumacaftor-rescued F508del-CFTR, 50% normalized Po  5.0
min; p 0.10; unpaired t test) (Fig. 2, E and G).
As we reported previously (32), when used acutely, ivacaftor
(10 M) initially potentiated markedly low temperature-res-
cued F508del-CFTR to achieve Po values similar to those of
wild-type CFTR in the absence of the small molecule (Fig. 2, A
and I). However, ivacaftor-potentiated F508del-CFTR deacti-
vated noticeably faster when compared with the absence of the
drug (Fig. 2, E and I). Acute treatment of lumacaftor-rescued
F508del-CFTRwith ivacaftor (10M) also potentiatedPomark-
edly to attain wild-type levels of channel activity (Fig. 2, A and
K). Comparison of normalized Po values reveals that channel
activities of ivacaftor-potentiated lumacaftor-rescued F508del-
CFTR and ivacaftor-potentiated low temperature-rescued
F508del-CFTR were similar (low temperature-rescued F508del-
CFTR  acute ivacaftor, 50% normalized Po  3.5 min;
lumacaftor-rescued F508del-CFTR acute ivacaftor, 50% nor-
FIGURE 1. The single-channel activity of wild-type CFTR, F508del-CFTR, and G551D-CFTR. A, representative CFTR single-channel recordings in excised
inside-out membrane patches from BHK cells expressing wild-type and F508del-CFTR and FRT cells expressing G551D-CFTR. In this and subsequent figures
using the patch clamp technique, ATP (1mM) and PKA (75 nM)were continuously present in the intracellular solution, temperaturewas 37 °C, voltagewas50
mV, and therewas a largeCl concentrationgradient across themembranepatch (internal [Cl], 147mM; external [Cl], 10mM). Thedotted lines indicatewhere
channels are closed, and downward deflections of the traces correspond to channel openings. B, representative current amplitude histograms of single CFTR
Cl channels in excised membrane patches from cells expressing wild-type (WT) CFTR, F508del-CFTR, and G551D-CFTR after filtering digitally at 50 Hz. The
continuous lines represent the fit of Gaussian distributions to the data. The closed (C) and open (O) channel amplitudes are indicated; S-CS, a subconductance
state of F508del-CFTR. For F508del-CFTR, a small leak current shifted the closed channel amplitude to 0.4 pA. (Current amplitude is calculated from the
difference between the closed and open current amplitudes determined from the fit of Gaussian distributions to the data). C and D, summary single-channel
current amplitude (i) and Po or Po(app) data. Symbols, individual values; columns, means S.E. (error bars) (wild type, n 10; F508del-CFTR, n 21; G551D-CFTR,
n 15); *, p 0.05 versuswild-type CFTR; #, p 0.05 versus F508del-CFTR fully open state; ND, not determined.
Instability of F508del-CFTR
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malized Po 5.5min; p 0.05; unpaired t test) (Fig. 2, I andK).
Nevertheless, Po values declined noticeably faster in the pres-
ence of ivacaftor (Fig. 2, G and K).
In 8 of 12 experiments where F508del-CFTR Cl channels
were rescued by chronic co-incubation with lumacaftor (3 M)
and ivacaftor (1 M) for 24 h at 37 °C, we observed a strikingly
different result (Fig. 2,M andN). First, the Po of F508del-CFTR
following complete channel activation was greatly elevated and
similar to that of wild-type CFTR (p  0.39; unpaired t test)
(Fig. 2, A and M). Second, the temporal stability of these
F508del-CFTR Cl channels was noticeably increased. Analy-
sis of normalized Po values indicates that 9 min after complete
channel activation, F508del-CFTR rundown was markedly
slowed andhadnot reached 50%complete (Fig. 2M). This result
contrasts markedly with F508del-CFTR rescued by low tem-
perature or lumacaftor, where F508del-CFTR rundown was
complete or all but complete within 9 min (Fig. 2, E and G). It
also contrasts with the destabilization of F508del-CFTR tran-
sepithelial Cl currents in CF airway epithelia chronically
treated with lumacaftor and ivacaftor (24, 25). One possible
explanation for this result is that in single-channel studies, we
might have observed aminor population of F508del-CFTR Cl
channels over a short time scale that does not represent the bulk
behavior of the protein. Consistent with this idea, in 4 of 12
experiments, chronic co-incubation with lumacaftor and iva-
caftor failed to rescue F508del-CFTR channel activity and sta-
bility. In these four experiments, F508del-CFTR Cl channels
deactivated completely after activation at 27 °C, before temper-
ature was increased to 37 °C for analysis of channel activity and
temporal stability. We therefore decided to investigate bulk
CFTR properties using purified proteins and membrane
patches and polarized epithelia with large numbers of active
channels that were followed over longer time periods.
Action of Ivacaftor and Lumacaftor on the Thermal Stability
of CFTR Protein in Membranes and after Purification—To
investigate the thermal stability of CFTR protein, we overex-
pressed wild-type CFTR, F508del-CFTR, and G551D-CFTR in
yeast cells and purified CFTR-containing membranes (36, 37).
To monitor the thermal stability of CFTR in membranes, we
exploited a C-terminal GFP tag as a reporter. Detergent-solu-
bilized CFTR was unfolded by incubation at different temper-
atures between 15 and 80 °C in 5 °C increments for 5 min at
each temperature before analysis by SDS-PAGE. Thermal
unfolding caused the appearance of SDS-resistant CFTR aggre-
gates similar to those observed for CFTR (38) and other mem-
brane proteins subject to equivalent treatment (39).
Fig. 4A shows a representative SDS-polyacrylamide gel used
to analyze the thermal stability of G551D-CFTR and Fig. 4,
B–D, shows summary data for wild-typeCFTR, F508del-CFTR,
and G551D-CFTR. Fig. 4B demonstrates that wild-type and
FIGURE 2. Impact of ivacaftor and lumacaftor on the temporal instability of F508del-CFTR in excised inside-out membrane patches. A, C, E, G, I, K, and
M, time courses of Po; B, D, F, H, J, L, and N, representative recordings of wild-type CFTR, F508del-CFTR, and G551D-CFTR in excised inside-out membrane
patchesmade in the continuous presence of ATP (1mM) and PKA (75 nM) at 37 °C once channel activationwas complete. For wild-type CFTR andG551D-CFTR,
membranepatcheswereexcised, andchannelswere activatedand studied, all at 37 °C. For F508del-CFTR,membranepatcheswereexcised, andchannelswere
activated and potentiated at 27 °C to delay temperature-dependent channel deactivation. Only after F508del-CFTR was fully activated and potentiated was
temperature increased to 37 °C and temporal stability evaluated. For F508del-CFTR, plasma membrane expression was rescued by incubation at 27 °C for
48–72h (E, F, I, and J) or by treatmentwith lumacaftor (VX-809; 3M) at 37 °C for 24h (G,H,K, L,M, andN). F508del-CFTRCl channelswere either acutely treated
with ivacaftor (aVX-770; 10M) (I–L) or chronically incubatedwith ivacaftor (cVX-770; 1M) together with lumacaftor (VX-809; 3M) at 37 °C for 24 h (M andN).
In E, G, I, K, andM, the left and right ordinates show Po (bars) and normalized Po (circles), respectively; Po values were normalized to that measured immediately
when temperature reached 37 °C (t 0–30 s); horizontal dotted lines indicate 50% normalized Po. For wild-type and F508del-CFTR, Po values were calculated
for each 30-s interval, whereas for G551D-CFTR, Po(app) values were calculated. Data are means S.E. (error bars) (wild-type CFTR, n 8; G551D-CFTR, n 8;
F508del-CFTR, n 10; F508del-CFTR, VX-809, n 7; F508del-CFTR, aVX-770, n 4; F508del-CFTR, VX-809 aVX-770, n 4; F508del-CFTR, VX-809 cVX-770,
n 8). In B,D, F,H, J, L, andN, arrowsdenote the closed channel state, and downward deflections correspond to channel openings. InA, E, and I, somedatawere
originally published in Wang et al. (32) (A, n 4; E, n 5; I, n 4); other data are newly acquired.
Instability of F508del-CFTR
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G551D-CFTR developed aggregation-detected unfolding curves
with midpoints around 60 °C. In the initial stages of thermal
denaturation, G551D-CFTR appeared slightlymore stable than
wild-type CFTR (Fig. 4B). By contrast, the unfolding transition
of F508del-CFTR was broader and occurred at lower tempera-
tures (Fig. 4B). Consistent with the functional stability of
F508del-CFTR andG551D-CFTR (Fig. 2), these data argue that
G551D-CFTR is stable, whereas F508del-CFTR is an unstable
membrane protein.
To begin to investigate the action of lumacaftor on the ther-
mal stability of F508del-CFTR protein, we incubated yeast cells
expressing F508del-CFTR with lumacaftor (2 M for 20 min at
4 °C). In contrast to functional studies, where acute and chronic
effects of small molecules were evaluated, it was only feasible to
test the acute effects of small molecules on CFTR protein pro-
duced in the yeast expression system. Fig. 4D demonstrates that
lumacaftor induced some thermostabilization of F508del-
CFTR, most noticeable around the midpoint of F508del-CFTR
protein unfolding (control, 60.9  1.8 °C; lumacaftor, 63.9 
2.8 °C; n  3). By contrast, ivacaftor (2 M for 20 min at 4 °C)
was without effect on F508del-CFTR protein in this assay (n 3)
(77). Consistent with previous results (24), ivacaftor (2 M for
20 min at 4 °C) induced a small, but significant, destabilization
of G551D-CFTR (midpoint: control, 69.4  2.9 °C; ivacaftor,
66.1 1.1 °C; n 3). Thus, ivacaftor restores to G551D-CFTR
a thermal sensitivity similar to that of wild-type CFTR (Fig. 4C).
To better understand the impact of the F508del mutation on
the thermal stability of CFTR protein, we applied a more sensi-
tive stability assay using the cysteine-reactive fluorescent dye
CPM (40) to purified CFTR protein solubilized from yeast cell
membranes (Fig. 5, A and B). In aqueous buffers, CPM fluores-
cence is low, but it increases greatly upon formation of covalent
adducts with cysteine residues in a protein (40). Fig. 5A dem-
onstrates that CPM fluorescence increased noticeably when
purified wild-type CFTR protein was added to a CPM-contain-
ing buffer as a result of adduct formation with surface-exposed
cysteine residues. Complete denaturation of wild-type CFTR
protein by guanidine HCl led to a 4-fold increase in CPM fluo-
rescence over a period of about 30 min at 10 °C (Fig. 5A); half-
time for cysteine adduct formation was about 7 min. Subse-
quent heating of the guanidineHCl-denatured wild-type CFTR
protein did not increase further CPM fluorescence but rather
led to a loss of fluorescence because of thermal quenching (Fig.
5A).
By contrast, in the absence of guanidine HCl, folded wild-
typeCFTRprotein produced only a small increase inCPM fluo-
rescence at 10 °C (Fig. 5A). Only with thermal denaturation of
the purified wild-type CFTR protein by heating was a 3–4-fold
increase in CPM fluorescence observed (Fig. 5A). After com-
plete unfolding of purified wild-type CFTR protein at around
53 min, when the sample had reached 60 °C, a decrease in
CPM fluorescence was observed due to thermal quenching.
Because CPM fluorescence at any given time is determined by
(i) the kinetics of protein unfolding, (ii) CPM-cysteine adduct
formation,which is temperature-dependent, and (iii) the rate of
heating, which leads to large hysteresis effects, this stability
assay will produce different midpoint temperatures for protein
unfolding, depending on these parameters. Hence, the mid-
point temperature determined for the purified wild-type CFTR
protein from the original data in Fig. 5Awill be somewhat unre-
liable and, because of hysteresis, will probably overestimate the
stability of purified wild-type CFTR protein. Hence, the assay
was used for comparative purposes only under conditions
where experimental parameters, such as the rate of heating,
were constant (Fig. 5).
Fig. 5C demonstrates that purified F508del-CFTR protein
displayed striking thermal destabilization compared with wild-
type CFTR protein with a midpoint temperature shift of about
10 °C and a broader unfolding transition in the CPM assay. By
contrast, purified G551D-CFTR protein exhibited cooperative
unfolding with a stability comparable with or even greater than
that of purified wild-type CFTR protein (Fig. 5C). Interestingly,
the overall comparative stability of the purified CFTR protein
was not noticeably different from that ofCFTRprotein inmem-
branes assayed by SDS-PAGE (Figs. 4 and 5C). Hence, therewas
no evidence for effects of the protein purification process per se
on CFTR stability. Nevertheless, the destabilizing effects of
detergent solubilization and the stabilizing effects of a lipid
bilayer on membrane proteins have been described frequently
FIGURE 3. Stability of wild-type and F508del-CFTR in excised inside-out
membrane patches at 37 °C. Shown are representative 9-min single-chan-
nel recordings (A and B) and corresponding Po time courses (C) of wild-type
and low temperature-rescued F508del-CFTR in excised inside-outmembrane
patches following full channel activation. ATP (1 mM) and PKA (75 nM) were
continuously present in the intracellular solution; temperaturewas 37 °C. InA
and B, four 2-s single-channel records labeled 1–4 indicated by bars are dis-
played on an expanded time scale below the 9-min recording to indicate
channel activity at the beginning, in the middle, and at the end of the exper-
iment. The arrows and dotted lines indicate where channels are closed, and
downward deflections correspond to channel openings. In C, Po values were
calculated in 20-s intervals. Formean data, see Fig. 2, and for further informa-
tion, see Figs. 1 and 2.
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(41). For CFTR, we observed similar behavior (37), with ther-
mal stabilization of wild-type CFTR and F508del-CFTR in the
presence of a lipid bilayer (Fig. 6). Of note, the difference in
stability betweenwild-typeCFTR and F508del-CFTR is less in a
lipid bilayer, suggesting that detergent might exacerbate the
instability of F508del-CFTR protein.
Fig. 5E demonstrates that treatment of purified F508del-
CFTR protein with lumacaftor (2 M for 20 min at 4 °C) par-
FIGURE 4. Thermal stability of full-length CFTR protein in membranes and the effects of ivacaftor and lumacaftor. A, representative gel showing the
thermal stability of G551D-CFTR in solubilized microsomes probed by the formation of SDS-resistant aggregates (top arrow) and the concomitant disappear-
ance of the monomeric CFTR band (bottom arrow). The position of the 250 kDa molecular mass marker is shown. CFTR was detected by the fluorescence of
tagged GFP, which is stable up to 80 °C under the conditions used. B–D, summary data showing the thermal stability of wild-type CFTR, F508del-CFTR, and
G551D-CFTR, the effects of ivacaftor (VX-770; 2M) on the thermal stability of G551D-CFTR and lumacaftor (VX-809; 2M) on the thermal stability of F508del-
CFTR. Data are means S.E. (error bars) (n 3).
FIGURE 5.F508del accelerates the thermal denaturationofpurifiedCFTRprotein.A, unfoldingof purifiedwild-typeCFTRprotein by thermal and chemical
denaturationdetectedby changes inCPM fluorescence. The continuous anddashed lines showpurifiedwild-typeCFTRprotein inDDM-containingbuffer in the
absence and presence of 4 M guanidine HCl. The experiment was initiated by injecting CPM dye into a cuvette containing purified wild-type CFTR protein at
10 °C and monitoring CPM fluorescence for 30 min (period A). At the end of period A, the purified wild-type CFTR protein was heated to 78 °C over a 30-min
interval (period B). Numbers indicate changes in CPM fluorescence as follows: 1, background fluorescence of CPM in buffer unbound to protein; 2, kinetics of
CPMbinding to solvent-exposed cysteine residues; 3, initial thermal quenching of CPM fluorescence as purifiedwild-type CFTR protein is heated; 4, increase of
CPM fluorescence as purified wild-type CFTR protein unfolds, exposing more cysteine residues to solvent; and 5, continued thermal quenching of CPM
fluorescence after complete unfolding of wild-type CFTR protein. B, silver-stained SDS-PAGE of purified protein samples for WT CFTR, F508del-CFTR, and
G551D-CFTR. Wild-type CFTR and G551D-CFTR were purified by two chromatography steps, and F508del-CFTR was purified by one step. The arrow indicates
the expected position of the main contaminating protein, ribosomal protein L3, which was removed by the second chromatography step. C–E, unfolding
transitions of purified CFTR protein determined by changes in CPM fluorescence show the effects of F508del and G551D and the actions of ivacaftor (VX-770;
2 M) and lumacaftor (VX-809; 2 M). Samples of purified CFTR protein were heated at a rate of 1.2 °C/min. Data are means  S.E. (error bars) (n  3). F,
concentration dependence of lumacaftor-induced stabilization of purified F508del-CFTR protein. Filled circles, data from individual experiments.
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tially recovered protein thermostability similar to the drug’s
effects on F508del-CFTR in membranes (Fig. 4D). However,
analysis of the concentration dependence of this effect indi-
cated that maximal recovery of F508del-CFTR protein stability
was achieved at about 2 M lumacaftor (Fig. 5F). There was no
narrowing of the unfolding transition after the addition of
lumacaftor (Fig. 5E). Interestingly, the addition of nucleotide (2
mM ATP) restored a similar amount of stability to purified
F508del-CFTR protein as lumacaftor (2 M), and the effects
were not synergistic (n  3) (77). In contrast to the effects of
lumacaftor, ivacaftor (2 M for 20 min at 4 °C) caused a small,
but significant, thermo-destabilization of purified F508del-
CFTR protein (Fig. 5E). Consistent with previous results (24)
and Fig. 4C, ivacaftor (2 M for 20 min at 4 °C) also caused a
small, but significant, destabilization of purified G551D-CFTR
protein, restoring wild-type levels of protein stability to the
mutant protein (Fig. 5D). Thus, F508del exerts similar effects
on purified CFTR protein and single CFTR Cl channels,
whereas lumacaftor restores some stability to both pure protein
and single CFTR Cl channels, but ivacaftor destabilizes them.
Interestingly, the combination of both drugs added acutely
neither stabilized nor destabilized the purified protein. It is
possible that the drugs mutually cancel out. However,
lumacaftor must be given chronically to cells to rescue
F508del-CFTR. For reasons of cost, it was not possible to
grow yeast cells in the presence of lumacaftor in sufficient
numbers to purify F508del-CFTR.
F508del-CFTR Exhibits Two Populations of Cl Channels
after Chronic Treatment with Lumacaftor and Ivacaftor—To
investigate the effects of lumacaftor and ivacaftor on a popula-
tion of F508del-CFTR Cl channels, we studied large numbers
of active channels in excised membrane patches and transepi-
thelial Cl currents in polarized epithelia. Fig. 7A shows the
time course of F508del-CFTRCl currents in an excised inside-
outmembrane patch containingmultiple active F508del-CFTR
Cl channels; similar results were observed in three other
experiments. The plasma membrane expression of these
F508del-CFTR Cl channels was rescued by chronic incuba-
tion of baby hamster kidney (BHK) cells expressing F508del-
CFTR with lumacaftor (3 M) and ivacaftor (1 M) for 24 h at
37 °C. Immediately following CFTR activation with PKA (75 nM)
FIGURE 6.Thermostability of purifiedWTCFTRandF508del-CFTR after reconstitutionwith lipid.A and B, assessment of the stability of purifiedwild-type
CFTR and F508del-CFTR using the thermal gel assay and detection of the GFP reporter tag fluorescence. An aggregate band A appears at higher temperatures
with the concomitant disappearance of the monomer band M and an intermediate band. The positions of the 250 and 130 kDa molecular mass markers are
indicated by the yellow bars for WT CFTR; in all other panels, only the 250 kDa marker is indicated. C, evaluation of the stability of purified wild-type and
F508del-CFTR using CPM fluorescence. Data are means S.E. (error bars) (n 3); for clarity, only one-half of the error bars are shown.
FIGURE 7. Instability of F508del-CFTR Cl currents in excised inside-out
membrane patches. A and B, representative long duration recordings of
F508del-CFTR Cl currents and channels in excised inside-out membrane
patches following F508del-CFTR rescue by treatment of cells with lumacaftor
(3M) and ivacaftor (1M) for 24 h at 37 °C. F508del-CFTR Cl channels were
activated fully with ATP (1 mM) and PKA (75 nM) at 27 °C before the tempera-
ture was increased to 37 °C and the recordings commenced. ATP (1 mM) and
PKA (75 nM) were continuously present in the intracellular solution for the
duration of the recordings. Beneath each 20-min recording, the indicated
10-s period is shown on an expanded time scale. The dotted lines indicate
where channels are closed, and downward deflections of the traces corre-
spond to channel openings. In A, the continuous gray line shows the fit of a
single exponential function to determine the time constant for the deactiva-
tion of F508del-CFTR Cl currents. Similar results were observed in other
experiments (F508del-CFTR Cl currents, n 3; F508del-CFTR Cl channels,
n 5).
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and ATP (1 mM) at 37 °C, large numbers of F508del-CFTR Cl
channels were observed (Fig. 7A). Despite the continuous pres-
ence of ATP and PKA in the intracellular solution, over time
there was a progressive loss of F508del-CFTR channel activity
with a time constant of 405 s (Fig. 7A). After about 15min, only
two F508del-CFTR Cl channels remained. Their behavior,
including gating pattern and partial openings to a subconduc-
tance state, resembled that of low temperature-rescued
F508del-CFTR Cl channels that had undergone channel run-
down at 37 °C (Figs. 3 and 7A). As we reported previously (32),
once F508del-CFTR Cl channels had undergone rundown,
they could not be reactivated with fresh ATP and PKA.
In six excised inside-outmembrane patches with small num-
bers of F508del-CFTR Cl channels studied over a prolonged
period, F508del-CFTR rescued by chronic treatment with
lumacaftor and ivacaftor exhibited a different pattern of behav-
ior. Fig. 7B shows one such example. In this recording, ATP (1
mM) and PKA (75 nM) activated a small number of F508del-
CFTR Cl channels, but these F508del-CFTR Cl channels
possessed high activity and greater temporal stability with the
result that after 15 min, the remaining F508del-CFTR Cl
channel had a gating pattern characterized by frequent pro-
longed bursts of channel openings (Fig. 7B). The high activity
and notable stability of these F508del-CFTR Cl channels are
reminiscent of those observed in Fig. 2 (M and N), following
chronic treatment with lumacaftor (3 M) and ivacaftor (1 M)
for 24 h at 37 °C.We interpret these data to suggest that chronic
treatment with lumacaftor and ivacaftor restores high levels of
channel activity and prolonged stability to a small subpopula-
tion of F508del-CFTR Cl channels. However, the majority of
rescued F508del-CFTR Cl channels are relatively unstable at
37 °C.
To explore this hypothesis, we studied CFTR-mediated tran-
sepithelial Cl currents in Fischer rat thyroid (FRT) epithelia
expressing F508del-CFTR. We rescued the apical membrane
expression of F508del-CFTR by treating FRT epithelia with
lumacaftor (3M) for 24 h at 37 °C and either acutely or chron-
ically exposed these FRT epithelia to ivacaftor (1 M). As con-
trols, we studied FRT epithelia expressing wild-type CFTR and
G551D-CFTR. To identify cAMP-activated Cl currents car-
ried by CFTR, we used the thiazolidinone CFTR inhibitor
CFTRinh-172 (42). To specifically investigate the bulk popula-
tion of CFTR Cl channels present at the apical membrane,
FRT epithelia were treated with the protein synthesis inhibitor
cycloheximide (50g/ml) 15min beforemounting FRT epithe-
lia inUssing chambers and recordingCFTR-mediated transepi-
thelial Cl currents at t  0 h. The remaining FRT epithelia
were incubated with cycloheximide (50 g/ml) for 2, 4, or 6 h
before use. Cycloheximide treatment was without effect on epi-
thelial integrity (as measured by transepithelial resistance; Rt)
(e.g. for wild-type CFTR-expressing FRT epithelia chronically
treated with ivacaftor: at 0 h, Rt 1.79 0.32 kiloohms cm2; at
6 h, Rt 3.33 0.96 kiloohms cm2; n 6).
In wild-type CFTR expressing FRT epithelia, forskolin (10
M) activated rapidly large CFTR-mediated Cl currents of
similar magnitude in epithelia acutely or chronically treated
with ivacaftor (1 M) (Fig. 8, A and B). The decline of CFTR-
mediated Cl current after chronic ivacaftor treatment (Fig.
8B) might be a consequence of treating FRT chronically with a
drug (43), CFTR inhibition by high concentrations of potentia-
tors (44), or the dephosphorylation of CFTR (for discussion, see
Ref. 45). Consistent with previous results (24, 25), when wild-
type CFTR-expressing FRT epithelia were chronically treated
with ivacaftor (1 M), CFTR Cl currents were not potentiated
when ivacaftor (1M)was subsequently added acutely (Fig. 8B).
Fig. 8C demonstrates that therewas a slow, steady decline in the
magnitude of ivacaftor-potentiated CFTR-mediated Cl cur-
rents over 6 h, and the rate of decline was unaffected by pre-
treatment with ivacaftor (1 M) (p 0.084). However, chronic
ivacaftor treatment enhanced themagnitude of baseline Isc 2.8-
fold in FRT epithelia expressing wild-type CFTR (Fig. 8D). For
two reasons, this enhanced baseline Isc was CFTR-dependent;
first, its inhibition by CFTRinh-172 (control, Isc  41  9
A/cm2; CFTRinh-172 (10 M), Isc  20  3 A/cm2; n  6)
and, second, the attenuation of baseline Isc in FRT epithelia
expressing lumacaftor-rescued F508del-CFTR and G551D-
CFTR (Fig. 8, H and L).
Fig. 8E demonstrates that forskolin (10 M) activated small
CFTR-mediated transepithelial Cl currents in lumacaftor-
rescued F508del-CFTR FRT epithelia that were potentiated by
acute treatment with ivacaftor (1 M). However, over a 6-h
period in the continuous presence of cycloheximide (50g/ml),
the magnitude of the ivacaftor-potentiated CFTR-mediated
Cl current declined 3.9-fold (Fig. 8, E and G). By contrast,
when F508del-CFTR-expressing FRT epithelia were chroni-
cally treated with lumacaftor (3 M) and ivacaftor (1 M) for
24 h at 37 °C, themagnitude of theCFTR-mediatedCl current
activated by forskolin (10 M) was initially increased markedly,
and at all time points the current was unaffected by acute treat-
ment with ivacaftor (1 M) (Fig. 8F). Fig. 8G demonstrates that
in cycloheximide-treated lumacaftor-rescued F508del-CFTR
FRT epithelia, CFTR-mediated Cl currents were initially
enhanced 1.8-fold compared with acute treatment with
ivacaftor (1 M). However, these enhanced CFTR-mediated
Cl currents in chronically treated F508del-CFTR epithelia
decayed significantly faster than those observed in F508del-
CFTR epithelia acutely treatedwith ivacaftor (1M) (p 0.001)
(Fig. 8G). As a control, we omitted cycloheximide (50 g/ml)
treatment. Fig. 8G demonstrates that in the absence of cyclo-
heximide, the magnitude of CFTR-mediated Cl current was
sustained. Interestingly, Fig. 8 (I–K) demonstrates that similar
results were observedwhenG551D-CFTR-expressing FRT epi-
thelia were chronically treated with ivacaftor (1 M). The mag-
nitude of CFTR-mediated Cl current was initially enhanced
1.6-fold, but it decayed significantly faster than that of G551D-
CFTR FRT epithelia acutely treated with ivacaftor (1 M) (p
0.036) (Fig. 8K). These data are consistent with previous results
demonstrating that chronic exposure of F508del-CFTR-ex-
pressing epithelia to ivacaftor destabilizes CFTR-mediated
Cl currents (24, 25). Thus, our data suggest that chronic
treatment of cells expressing recombinant F508del-CFTR
with ivacaftor restored high levels of channel activity and
prolonged stability only to a small subpopulation of F508del-
CFTR Cl channels.
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Discussion
This study investigated the instability of F508del-CFTR and
its rescue by lumacaftor and ivacaftor. We demonstrated that
F508del destabilized purified full-length CFTR protein by
about 10 °C and caused time-dependent deactivation of indi-
vidual CFTR Cl channels by altering channel gating and cur-
rent flow through theCFTRpore. Lumacaftor and ivacaftor had
complex effects on F508del-CFTR. Interpretation of the data
suggests that combination therapy with lumacaftor and iva-
caftor rescues a small subpopulation of F508del-CFTR Cl
channels.
Previous studies demonstrate that the F508del mutation
causes thermoinstability of isolated humanNBD1 (e.g. see Refs.
46–48). Biophysical studies of NBD1 thermal and chemical
denaturation identified two sequential steps inNBD1unfolding
and revealed that F508del targets the first step, leading to a
partially unfolded, aggregation-prone structure (47, 49). Com-
parison of the present results with previous studies suggests
that F508del has greater impact on the thermostability of full-
length CFTR protein than isolated human NBD1 (NBD1,
6–8 °C (47, 48); full-length CFTR, 10 °C (present study)).
One potential explanation for this difference is the experimen-
tal conditions employed to investigate the thermostability of
full-lengthCFTRprotein.Nevertheless, the greater thermosen-
sitivity of full-length F508del-CFTR protein is consistent with
the disruption of domain-domain interactions critical for cor-
rect CFTR assembly and function following the loss of Phe-508
(8–11, 48, 50).
Single-channel studies using excised membrane patches and
planar lipid bilayers highlight the consequences of F508del-
CFTR instability for channel function. At 37 °C, F508del-CFTR
Cl channels deactivate promptly, leading to an irreversible
loss of channel activity in the continuous presence of PKA and
ATP (e.g. see Ref. 34) (present study). Consistent with the data
of Aleksandrov et al. (34), but not that of Wang et al. (51) and
Liu et al. (52), we found that the deactivation of F508del-CFTR
Cl channels involved both changes in channel gating and cur-
rent flow through open channels. Moreover, persistence of
F508del-CFTR at the plasma membrane at 37 °C is consider-
ably longer (t1⁄2  4 h) (14) than its loss of function in cell-free
membrane patches (5 min) (present study), concurring with
the conclusion that F508del-CFTR has inherent instability
when activated (52). Interestingly, several studies have identi-
fied revertant (second site) mutations in cis with F508del,
including missense mutations and deletions, which abrogate
the deactivation of F508del-CFTR Cl channels (34, 51–53).
Taken together, these data argue that F508del-CFTR thermoin-
stability is a consequence of changes inCFTR structure, not loss
of F508del-CFTR tethering to CFTR-interacting proteins (54).
F508del is located at a critical interface in the CFTR gating
pathway, which transduces conformation changes in the NBDs
to the membrane-spanning domains (MSDs) to control gating
FIGURE 8. Deactivation of CFTR-mediated transepithelial Cl currents after acute or chronic ivacaftor treatment. Shown are representative Ussing
chamber recordings of WT CFTR (A and B), lumacaftor-rescued (VX-809; 3M for 24 h at 37 °C) F508del-CFTR (E and F), and G551D-CFTR (I and J). FRT epithelia
were incubated for 24 h at 37 °C in the absence (A, E, and I; Acute) or presence (B, F,and J; Chronic) of ivacaftor (VX-770; 1 M); F508del-CFTR-expressing FRT
epithelia were co-incubatedwith lumacaftor and ivacaftor. Fifteenminutes before t 0 h, FRT epithelia were treatedwith cycloheximide (50g/ml), added to
both the apical and basolateral solutions. At the indicated times, FRT epithelia weremounted in Ussing chambers, and CFTR Cl currents were activated with
forskolin (Fk; 10 M), potentiated with ivacaftor (VX-770 (770); 1 M), and inhibited by CFTRinh-172 (C172; 10 M); continuous lines indicate the presence of
different compounds in the apical solution; cycloheximide (50 g/ml) was present in the apical and basolateral solutions during Isc recordings. Data are
normalized tobaseline current so that	Isc represents the change in transepithelial current after CFTR activationby forskolin.C,G, and K (Summary),magnitude
of ivacaftor-potentiated 	Isc for WT CFTR, lumacaftor-rescued F508del-CFTR, and G551D-CFTR at different times after cycloheximide (50 g/ml) treatment.
Data aremeans S.E. (error bars) (n 5–10); the continuous and dotted lines show the fits of linear and single exponential functions, respectively, toWT CFTR,
F508del-CFTR, andG551D-CFTRCl currents acutely and chronically treatedwith ivacaftor.G, as a control, themagnitudeof lumacaftor-rescued F508del-CFTR
Cl current chronically treated with ivacaftor (1 M for 24 h at 37 °C) but untreated with cycloheximide is shown (0.1% (v/v) DMSO; CHX Ctrl). D, H, and L
(Baseline), magnitude of absolute Isc before CFTR activation for WT CFTR-, lumacaftor-rescued F508del-CFTR-, and G551D-CFTR-expressing FRT epithelia
acutely or chronically treated with ivacaftor. Symbols, individual values; columns, means S.E. (n 5–10).
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of the channel pore (9, 10). Thus, changes in channel gating
during F508del-CFTR deactivation might be a consequence of
disabled communication between the NBDs and MSDs. How-
ever, the literature suggests two alternative explanations: first,
destabilization of the full and partial NBD1-NBD2 dimer con-
figurations (55) in the ATP-driven NBD dimerization model of
channel gating (4, 56) and, second, defective regulation of
F508del-CFTR Cl channels by PKA-dependent phosphoryla-
tion of the R domain (57). Disabled communication between
the NBDs and MSDs also provides a potential explanation for
instability of the CFTR pore during F508del-CFTR deactiva-
tion. Cui et al. (58) identified salt bridges between transmem-
brane segments in the MSDs that stabilize the open channel
configuration. We speculate that defective signaling from the
NBDs during F508del-CFTR deactivation might destabilize
these salt bridges, favoring opening of the CFTR pore to
a subconductance state. Alternatively, defective signaling
from the NBDs might prevent full opening of a gate located
in the pore constriction (59). Future studies should explore
these possibilities.
Lumacaftor and ivacaftor are the first drugs for CF designed
to directly target defects in CFTR. Lumacaftor acts cotransla-
tionally to allow some F508del-CFTR to escape intracellular
degradation and traffic to the plasma membrane (16). It also
acts posttranslationally to stabilize F508del-CFTR at the
plasma membrane (60). Consistent with this latter result, the
present results demonstrate that once at the plasmamembrane,
lumacaftor-rescued F508del-CFTR is more stable than low
temperature-rescued F508del-CFTR. The data argue that
lumacaftor binds directly to the mutated protein and stabilizes
it to some extent. This interpretation is further supported by
our experiments performed on single Cl channels and puri-
fied protein (Figs. 2–6) as well as previously published experi-
ments with N-terminal fragments of CFTR (61, 62). When
lumacaftor was added acutely to purified F508del-CFTR pro-
tein, its thermostabilization effect saturated at around 2 M,
which corresponds closely to the functional effects of the drug
added chronically (16). This direct correlation between thermal
stabilization and functional rescue of F508del-CFTR provides
some evidence that the principal defect of the F508delmutation
might be reduced thermostability, consistent with the results of
biophysical studies of NBD1 thermal and chemical denatur-
ation (47, 49).
Ivacaftor robustly potentiates CFTR channel gating to
restoreCl channel function toCFmutants (17, 63). In contrast
to other CFTR potentiators that enhance ATP-dependent
channel gating at the NBDs (33, 64), the action of ivacaftor is
ATP-independent (65, 66). Using computer modeling, Cholon
et al. (24) demonstrate that ivacaftor destabilizes the structure
of CFTR. Whereas this destabilization is beneficial to the rigid
structure ofG551D-CFTR, it is deleterious to the delicate struc-
ture of F508del-CFTR (24), providing an explanation for the
drug’s effects on purified CFTR protein and single channels
observed in the present study.
Our data raise the interesting possibility that chronic co-in-
cubation of cells expressing F508del-CFTR with lumacaftor
and ivacaftor rescues a small subpopulation of F508del-CFTR
Cl channels with distinct characteristics. Consistent with pre-
vious results (35), the single-channel activity of low tempera-
ture- and lumacaftor-rescued F508del-CFTRCl channels was
closely comparable. By contrast, F508del-CFTR Cl channels
rescued by chronic co-incubation with lumacaftor and iva-
caftor were characterized by greatly increased activity and tem-
poral stability. At the present time, we do not know the identity
of this subpopulation of F508del-CFTR Cl channels, nor
whether both populations are found in one cell, although this is
likely (67). The simplest interpretation of the data is that
chronic co-incubation with lumacaftor and ivacaftor directly
targets F508del-CFTR to rescue protein folding defects and
improve channel gating and stability. Consistent with this idea,
studies docking lumacaftor with CFTRhomologymodels argue
that it binds directly to CFTR at the NBD1-MSD1/2 interface
(22, 23, 68). Although the binding site for ivacaftor on CFTR is
currently unknown, single-channel studies of purified recom-
binant protein (65) argue that CFTR, itself, is targeted by iva-
caftor, whereas studies of wild-type CFTR and CF mutants
argue that amino acid sequences within the MSDs probably
form its binding site (63, 66). Thus, chronic co-incubation
would favor the interaction of lumacaftor and ivacaftor with
F508del-CFTR, potentially leading to improved correction of a
subset of F508del-CFTR Cl channels.
Alternatively, chronic co-incubationmight rescue a subpop-
ulation of F508del-CFTR Cl channels by affecting membrane
lipids. In support of this idea, Baroni et al. (69) demonstrated
that ivacaftor accumulates in the inner leaflet of lipid bilayers.
Moreover, Abu-Arish et al. (67) identified two populations of
CFTR Cl channels at the plasma membrane distinguished by
their interaction with cholesterol-rich membrane microdo-
mains. Whereas the majority of CFTR Cl channels at the
plasma membrane were mobile, some demonstrated choles-
terol-dependent confinement (67). Future studies should
investigate further how membrane lipids modulate CFTR
expression, stability, and function and its interactionwith small
molecules.
In conclusion, the F508del mutation causes a large destabili-
zation of full-length CFTR protein, noticeably greater than that
reported previously for isolated NBD1 (46–48). Consistent
with these data, the time-dependent deactivation of F508del-
CFTR Cl channels in excised membrane patches at 37 °C
involves changes in both channel gating and Cl conductance.
Together, the data argue that the F508del mutation has wide
ranging impact on CFTR structure. The clinically approved
CFTR modulators lumacaftor and ivacaftor had complex
effects on CFTR stability. Of special note, chronic co-incuba-
tion of cells expressing F508del-CFTRwith lumacaftor and iva-
caftor greatly increased the activity and stability of a small sub-
population of F508del-CFTR Cl channels. The challenge for
the future is to identify strategies to convert the majority of
unstable F508del-CFTR Cl channels into this restored form.
Experimental Procedures
Cells and Cell Culture—Weused BHK cells stably expressing
wild-type and F508del human CFTR and FRT epithelial cells
stably expressing F508del and G551D human CFTR (70, 71).
Cells were generous gifts fromM. D. Amaral (University of Lis-
boa; BHK cells) and L. J. V. Galietta (InstitutoGianninaGaslini;
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FRT cells). Unless otherwise indicated, cells were cultured and
used as described previously (43, 72). When testing the effects
of chronic drug treatments on F508del-CFTR-expressing BHK
cells (but not F508del-CFTR-expressing FRT epithelia), the
fetal bovine serum concentration of media was reduced to 1%.
The single-channel behavior of wild-type human CFTR in
excisedmembrane patches fromdifferentmammalian cell lines
is equivalent (73).
Patch Clamp Experiments—CFTR Cl channels were
recorded in excised inside-out membrane patches using an
Axopatch 200A patch clamp amplifier and pCLAMP software
(both from Molecular Devices, Sunnyvale, CA) (74). The
pipette (extracellular) solution contained 140 mMN-methyl-D-
glucamine, 140 mM aspartic acid, 5 mM CaCl2, 2 mM MgSO4 ,
and 10 mM TES, adjusted to pH 7.3 with Tris ([Cl], 10 mM).
The bath (intracellular) solution contained 140 mM N-methyl-
D-glucamine, 3 mM MgCl2, 1 mM CsEGTA, and 10 mM TES,
adjusted to pH 7.3withHCl ([Cl], 147mM; free [Ca2] 108
M) and was maintained at 27 or 37 °C using a temperature-
controlled microscope stage (Brook Industries, Lake Villa, IL).
After excision of inside-outmembrane patches, we added the
catalytic subunit of PKA (75 nM) and ATP (1 mM) to the intra-
cellular solution within 2 min of patch excision to activate
CFTR Cl channels. To minimize channel rundown, we added
PKA to all intracellular solutions andmaintained the ATP con-
centration at 1 mM and clamped voltage at50 mV. To inves-
tigate the temporal stability of wild-type CFTR and G551D-
CFTR, membrane patches were excised, channels were
activated, and their stability was assessed all at 37 °C. However,
to study the instability of F508del-CFTR, membrane patches
were excised and activated at 27 °C to delay temperature-de-
pendent channel deactivation. In some experiments, F508del-
CFTR Cl channels were potentiated by the addition of iva-
caftor (10 M) to the intracellular solution in the continuous
presence of ATP (1mM) and PKA (75 nM). Once F508del-CFTR
Cl channels were fully activated and potentiated when using
ivacaftor, the temperature of the intracellular solution was
increased to 37 °C, which took 2–3 min. To monitor CFTR
temporal stability, we calculated Po and normalized Po in 30-s
intervals over a 9-min period (32). To investigate the temporal
stability of F508del-CFTR Cl currents, we studied membrane
patches containing multiple active channels over a 20-min
period.
For single-channel studies, we used membrane patches con-
taining5 active channels (wild-type CFTR, number of active
channels (n) 4; F508del-CFTR, n 5). To determine channel
number, we used themaximum number of simultaneous chan-
nel openings observed during the course of an experiment, as
described previously (33). Because of the extremely low activity
of G551D-CFTR (29, 30), we did not determine channel num-
ber for G551D-CFTR. Instead, we express G551D-CFTR chan-
nel activity as Po(app) (30).
We recorded, filtered and digitized data as described previ-
ously (74). To measure single-channel current amplitude,
Gaussian distributions were fitted to current amplitude histo-
grams. To measure Po, lists of open and closed times were cre-
ated using a half-amplitude crossing criterion for event detec-
tion, and dwell time histograms were constructed and fitted as
described previously (74). For the purpose of illustration, sin-
gle-channel records were filtered at 500 Hz and digitized at 5
kHz before file size compression (Fig. 1, 5-fold data reduction;
Figs. 2, 3, and 7, 50-fold).
Ussing Chamber Studies—CFTR-mediated transepithelial
Cl currents in FRT epithelia were recorded using a large Cl
concentration gradient to magnify current size without per-
meabilizing the basolateral membrane (72). FRT epithelia were
mounted in Ussing chambers (Warner Instrument Corp., Dual
Channel Chamber; Harvard Apparatus Ltd., Edenbridge, UK).
The solution bathing the basolateral membrane contained 140
mM NaCl, 5 mM KCl, 0.36 mM K2HPO4, 0.44 mM KH2PO4, 1.3
mMCaCl2, 0.5mMMgCl2, 10mMHEPES, and 4.2mMNaHCO3,
adjusted to pH 7.2 with Tris ([Cl], 149 mM). The solution
bathing the apical membrane was identical to that of the baso-
lateral solution with the exception that 133.3 mM sodium glu-
conate 2.5mMNaCl and 5mM potassium gluconate replaced
140 mM NaCl and 5 mM KCl, respectively, to create a transepi-
thelial Cl concentration gradient ([Cl], 14.8 mM). To com-
pensate for calcium buffering by gluconate, we used 5.7 mM
Ca2 in the apical solution. All solutions were maintained at
37 °C and bubbled continuously with 5% CO2.
After cancelling voltage offsets, we clamped transepithelial
voltage (referenced to the basolateral solution) at 0 mV and
recorded Isc continuously using an epithelial voltage clamp
amplifier (Warner Instrument Corp., model EC-825; Harvard
Apparatus Ltd.), digitizing data as described previously (75).
The resistance of the filter and solutions, in the absence of cells,
was subtracted from all measurements. Under the experimen-
tal conditions that we used, flow of current from the basolateral
to the apical solution corresponds to Cl movement through
openCFTRCl channels and is shown as an upward deflection.
For the purpose of illustration, Isc time courses are displayed as
	Isc with the Isc value immediately preceding forskolin addition
designated as 0A/cm2; file sizes were compressed by 100-fold
data reduction.
Thermal Gel Analysis—Microsomes from Saccharomyces
cerevisiae expressing GFP-tagged CFTR (36, 37) were solubi-
lized with 2% (w/v) dodecyl--D-maltoside (DDM) for 2 h and
then centrifuged at 100,000 
 g for 1 h at 4 °C. DDM-solubi-
lized material in the supernatant was collected and diluted 1:4
with CFTR buffer (50 mM Tris, pH 8.0, 10% (v/v) glycerol) to a
final concentration of 0.5% (w/v) DDM. The sample was then
placed into an Eppendorf tube in a water bath, and the temper-
ature was increased from 15 to 80 °C at 2.5 °C/min between
sampling temperatures. Every 5 °C, the sample was incubated
for 5min before a 20-l aliquot was taken and quenched imme-
diately on ice for 10 min before the addition of 20 l of SDS-
loading buffer. All of the samples collected at different temper-
atures were analyzed on the same SDS-polyacrylamide gel, and
CFTR-containing bandswere quantified using theGFP fluores-
cence signal and ImageJ software.
Protein Purification—CFTR protein was initially purified as
described by O’Ryan et al. (37) using DDM. The nickel-nitrilo-
triacetic acid-purified protein (first step) was then loaded onto
a pre-equilibrated 1-ml FLAG affinity column (Sigma) and
washedwith 10 column volumes of buffer before bound protein
was eluted with 100 g/ml FLAG peptide (Sigma) in the same
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DDM-containing buffer. The protein yield was about 20% of
the protein initially added to the FLAG affinity column. For the
F508del-CFTR protein, which had a lower level of expression,
the FLAG purification step was omitted. The purity of the final
fractions was assessed by SDS-PAGE (see Fig. 5B). Purified
CFTR protein was reconstituted with lipids as described (37).
CPM Binding Analysis—This fluorescence assay (40) is sen-
sitive to plasticizers that leach out of plastic.Hence, buffer com-
ponents, detergent-containing buffers, and stocks of the
fluorochrome N-[4-(7-diethylamino-4-methyl-3-coumarinyl)
phenyl]maleimide (CPM)were stored in glass containers; CPM
was stored in the dark at20 °C. Immediately before use, CPM
stock solutions were diluted into buffer using a glass microsy-
ringe. Dithiothreitol (DTT) was removed from buffers and pro-
tein-containing samples before the addition of CPM. CPM
had a measurable background fluorescence due to detergent
micelles (77). Hence, the buffer control signal was subtracted
from test signals. Protein at 5–7g/ml (about 25 nM)was added
to buffer containing CPM (0.7 g/ml, 2.4 M) and DDM (0.1%
w/v) (37). When used at10 g/ml (34 M), CPM concentra-
tion was without effect on themeasured unfolding transition of
CFTR. However, at higher CPM concentrations, the measured
unfolding transition of CFTR shifted to higher temperatures.
After incubation at 10 °C for 20 min, a temperature ramp of
1.5–2.5 °C/min was initiated. At faster heating rates, hysteresis
or lag was apparent, at least partly due to the finite time
required for CPM binding to occur. CPM fluorescence was
recorded using aCary Eclipse fluorimeterwith excitation at 387
nm (5-nm slit) and emission at 463 nm (5-nm slit) in a 150 l,
1-cm path length quartz fluorescence cuvette (Hellma).
Materials—Ivacaftor and lumacaftor were purchased from
Selleck Chemicals (Stratech Scientific Ltd., Newmarket, UK).
CFTRinh-172, cycloheximide and forskolin were purchased
from Sigma-Aldrich (Gillingham, UK), and PKA purified from
bovine heart was from Calbiochem (Merck Chemicals Ltd.,
Nottingham, UK). All other chemicals were of reagent grade
and supplied by Sigma-Aldrich.
ATP was dissolved in intracellular solution, forskolin in
methanol, and all other reagents in DMSO. Stock solutions
were stored at 20 °C with the exception of those of ATP,
which were prepared directly before each experiment. Imme-
diately before use, stock solutions were diluted to final concen-
trations, and, where necessary, the pH of the intracellular solu-
tion was readjusted to pH 7.3 to avoid pH-dependent changes
in CFTR function (73). Precautions against light-sensitive reac-
tions were observed when using CFTRmodulators. DMSOwas
without effect on CFTR activity (43, 74). Upon completion of
experiments, chambers were thoroughly cleaned before reuse
(for patch clamp studies, see Ref. 32); for Ussing chamber stud-
ies, soaked overnight in 3% (v/v) MucasolTM (Merz GmbH)
diluted in hot water before thorough washing with double-dis-
tilled water).
Data Analysis—Results are expressed as means  S.E. of n
observations. To test for differences between groups of data, we
used Student’s t test or an analysis of variance. Differences were
considered statistically significant when p 0.05. All tests were
performed using SigmaPlot (Systat Software Inc., Richmond,
CA).
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